Dermira, Inc. (NASDAQ:DERM) Downgraded by Zacks Investment Research to Sell
Zacks Investment Research downgraded shares of Dermira, Inc. (NASDAQ:DERM) from a hold rating to a sell rating in a research note released on Friday.
According to Zacks, “Dermira, Inc. is a specialty biopharmaceutical company. It is focused on bringing medical dermatology products to dermatologists and their patients. The Company markets topical small molecule therapeutics that target acne, sebaceous gland hyperactivity, and inflammatory skin diseases. Its late-stage product candidates comprise Cimzia which has completed Phase II clinical trials for the treatment of moderate-to-severe plaque psoriasis; DRM04 that is in a Phase IIb clinical trial for the treatment of hyperhidrosis or excessive sweating; and DRM01 which has completed a Phase IIa clinical trial for the treatment of acne. Dermira, Inc. is headquartered in Redwood City, California. “
A number of other research firms have also issued reports on DERM. BidaskClub lowered shares of Dermira from a buy rating to a hold rating in a research note on Monday, July 3rd. Needham & Company LLC reiterated a buy rating and issued a $46.00 target price on shares of Dermira in a research note on Tuesday, July 18th. Mizuho lowered their target price on shares of Dermira from $42.00 to $40.00 and set a buy rating on the stock in a research note on Thursday, May 25th. Cantor Fitzgerald started coverage on shares of Dermira in a research note on Thursday, June 22nd. They issued an overweight rating and a $45.00 target price on the stock. Finally, Evercore ISI started coverage on shares of Dermira in a research note on Thursday, June 29th. They issued an outperform rating and a $48.00 target price on the stock. Four analysts have rated the stock with a sell rating, one has issued a hold rating and six have issued a buy rating to the company. The company presently has an average rating of Hold and an average price target of $43.80.
Shares of Dermira (NASDAQ DERM) opened at 27.53 on Friday. The company’s 50-day moving average is $29.20 and its 200-day moving average is $30.98. Dermira has a 12 month low of $25.63 and a 12 month high of $38.75. The stock’s market capitalization is $1.14 billion.
In other Dermira news, CEO Thomas G. Wiggans sold 5,000 shares of the firm’s stock in a transaction on Friday, June 2nd. The shares were sold at an average price of $27.52, for a total value of $137,600.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, SVP Christopher M. Griffith sold 1,312 shares of the firm’s stock in a transaction on Monday, May 15th. The stock was sold at an average price of $27.07, for a total transaction of $35,515.84. The disclosure for this sale can be found here. Insiders sold a total of 16,312 shares of company stock worth $468,441 over the last 90 days. Company insiders own 13.30% of the company’s stock.
Hedge funds have recently bought and sold shares of the company. KCG Holdings Inc. bought a new stake in Dermira during the first quarter valued at about $215,000. Legal & General Group Plc raised its stake in Dermira by 16.3% in the first quarter. Legal & General Group Plc now owns 6,861 shares of the biopharmaceutical company’s stock valued at $236,000 after buying an additional 963 shares in the last quarter. Tocqueville Asset Management L.P. bought a new stake in Dermira during the first quarter valued at about $256,000. RidgeWorth Capital Management LLC bought a new stake in Dermira during the first quarter valued at about $297,000. Finally, Airain ltd bought a new stake in Dermira during the first quarter valued at about $317,000. Institutional investors own 84.54% of the company’s stock.
Dermira, Inc is a biopharmaceutical company. The Company is focused on the development of therapeutic solutions in medical dermatology to treat skin conditions, such as hyperhidrosis, psoriasis and acne. Its portfolio includes three late-stage product candidates: Cimzia (certolizumab pegol), glycopyrronium tosylate and olumacostat glasaretil.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Dermira Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.